Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients.
OBJECTIVE
To compare the effectiveness of two very low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsutism.


METHODS
Eighteen hirsute women were randomized into two different regimens of cyproterone acetate and ethinylestradiol in a reverse sequential pattern: group 1 (0.28 mg ethinylestradiol monthly), group 2 (0.32 mg ethinylestradiol monthly). Both groups received 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month.


METHODS
Hirsutism scores were measured according to the Ferriman and Gallwey scoring system and side-effects and complications were recorded during the 6 months of therapy. Ovulation was monitored by radioimmunoassay of estradiol, follicle stimulating hormone (FSH), luteinizing hormone (LH) and progesterone levels. The pituitary response was studied using a gonadotropin releasing hormone test.


RESULTS
Hirsutism scores decreased significantly in both groups at the end of the 6 months (-30%). All patients were anovulatory, as documented by the reduction of the LH, FSH, estradiol and progesterone levels. Pretreatment basal LH and FSH levels were higher than LH and FSH levels during the treatment. Side-effects were observed only occasionally with some differences between the two therapeutic regiments.


CONCLUSIONS
Both treatments greatly improve hirsutism, reduce clinical problems and side-effects, guarantee both anovulation and contraceptive effectiveness and afford an optimal control of the menstrual cycle.
Institute of Reproductive Physiology and Pathology, University of Bologna, Italy.
S
S
Venturoli
B
B
Ravaioli
A
A
Bagnoli
F M
FM
Colombo
S
S
Macrelli
I
I
Iadarola
F
F
Vianello
F
F
Mancini
C
C
Flamigni
D000328:Adult; D003279:Contraceptives, Oral, Sequential / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D045166:Estradiol Congeners / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012720:Severity of Illness Index
D003279:Contraceptives, Oral, Sequential; D045166:Estradiol Congeners; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; D011374:Progesterone; D017373:Cyproterone Acetate; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone